These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24077440)

  • 1. The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer.
    Belotte J; Fletcher NM; Awonuga AO; Alexis M; Abu-Soud HM; Saed MG; Diamond MP; Saed GM
    Reprod Sci; 2014 Apr; 21(4):503-8. PubMed ID: 24077440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.
    Nusrat O; Belotte J; Fletcher NM; Memaj I; Saed MG; Diamond MP; Saed GM
    Reprod Sci; 2016 Nov; 23(11):1484-1492. PubMed ID: 27122375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress.
    Saed GM; Fletcher NM; Jiang ZL; Abu-Soud HM; Diamond MP
    Reprod Sci; 2011 Dec; 18(12):1253-61. PubMed ID: 21701041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
    Li Z; Wang Q; Zhang W; Yang Z; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
    Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
    Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
    Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
    Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
    Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
    Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
    Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
    Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
    Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
    Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
    Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
    Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
    Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.